

Date: August 5, 2022

To,

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street.

Mumbai - 400 001

Scrip Code: 543434

To.

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G

Bandra Kurla Complex

Bandra (E), Mumbai - 400 051

Scrip Symbol: SUPRIYA

Dear Sir (s),

Sub: Intimation of Board Meeting under Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In terms of Regulation 29 (1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a meeting of the Board of Directors of the Company will be held on Friday, August 12, 2022, inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2022.

This is further to inform you that with reference to our letter dated June 29, 2022 and in accordance with the provisions of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time and the Company's Code of Conduct for Prevention of Insider Trading, the 'Trading Window' for dealing in the securities of the Company shall continue to remain closed till 48 hours after announcement of Unaudited Financial Results for the quarter ended June 30, 2022.

Kindly take the above said information on your records.

Thanking you,

Yours faithfully,

For Supriya Lifescience Limited

Shweta Singh

Company Secretary & Compliance Officer

Membership No.: A44973

Corporate Office: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai 400 063, Maharashtra, India.

Tel: +91 22 40332727 / 66942507 | Fax: +91 22 26860011 | GSTIN: 27AALCS8686A1ZX

CIN: L51900MH2008PLC180452 | E-mail: supriya@supriyalifescience.com | Website: www.supriyalifescience.com

Factory

: A-5/2, Lote Parshuram Industrial Area, M.I.D.C., Tal.-Khed, Dist. Ratnagiri, Pin: 415 722, Maharashtra, India. Tel: +91 2356 272299 | Fax: +91 2356 272178 | E-Mail: factory@supriyalifescience.com